Randomized Trialmoderate evidence
Metabolic benefits of ketohexokinase inhibition in individuals with MASLD: a randomized placebo-controlled crossover trial.
Nature metabolism·October 1, 2026·PMID 42844400
Why it mattersFructose metabolism is implicated in MASLD and insulin resistance, but direct evidence that inhibiting ketohexokinase improves metabolic endpoints in humans is limited. These results suggest a potential therapeutic pathway for metabolic liver disease and systemic insulin resistance.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled